Cargando…
Endocrinology and hormone therapy in breast cancer: Selective oestrogen receptor modulators and downregulators for breast cancer – have they lost their way?
Although tamoxifen has been an effective treatment for breast cancer, several novel anti-oestrogen compounds have been developed with a reduced agonist profile on breast and gynaecological tissues. These include selective oestrogen receptor modulators (SERMs; both 'tamoxifen-like' and ...
Autor principal: | Johnston, Stephen RD |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2005
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1143577/ https://www.ncbi.nlm.nih.gov/pubmed/15987442 http://dx.doi.org/10.1186/bcr1023 |
Ejemplares similares
-
Prevention of breast cancer using selective oestrogen receptor modulators (SERMs)
por: Powles, Trevor J
Publicado: (2006) -
Plasma oestrogens and oestrogen receptors in breast cancer patients.
por: Mason, R. C., et al.
Publicado: (1985) -
An overview of menopausal oestrogen–progestin hormone therapy and breast cancer risk
por: Lee, S A, et al.
Publicado: (2005) -
Oestrogen receptor activity in hormone-dependent breast cancer during chemotherapy
por: Chic, Nuria, et al.
Publicado: (2021) -
Endocrinology and hormone therapy in breast cancer: Endocrine therapy in premenopausal women
por: Pritchard, Kathleen
Publicado: (2005)